Cibinetide
Erythropoietin receptor agonist
From Wikipedia, the free encyclopedia
Cibinetide (INN; USAN; developmental code name ARA-290) is an erythropoietin receptor agonist which is under development for the treatment of a variety of different medical conditions.[1][2][3][4] It was also under development for the treatment of depressive disorders, but development for this indication was discontinued.[1] The drug is under development by Araim Pharmaceuticals.[1][2] Modified derivatives with a longer duration of action have also been developed.[5]
Other namesARA-290; ARA290; PHBSP; pHBSP peptide; pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; Pyroglutamate helix B surface peptide; UEQLERALNSS
| Clinical data | |
|---|---|
| Other names | ARA-290; ARA290; PHBSP; pHBSP peptide; pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; Pyroglutamate helix B surface peptide; UEQLERALNSS |
| Drug class | Erythropoietin receptor agonist[1][2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C51H84N16O21 |
| Molar mass | 1257.324 g·mol−1 |
| 3D model (JSmol) | |
| |
| |